For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
29
views
16
references
 Top references
cited by
22
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
0 collections
    0
    shares
      588
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Pyrotinib is a newly-developed irreversible pan-ErbB receptor tyrosine kinase inhibitor. This study reported the first real-world data of pyrotinib-based therapy in metastatic human epidermal growth factor receptor 2 (HER2)-positive (BC), focusing on efficacy in lapatinib-treated patients and in brain metastasis. Methods One hundred thirteen patients with metastatic HER2-positive BC treated with pyrotinib-based therapy in Fudan University Shanghai Cancer Center under non-clinical trial settings from September 1, 2018 to March 1, 2019 were included.

          Related collections

          Most cited references16

          • Record: found
          • Abstract: found
          • Article: not found

          Breast Cancer Treatment

          Adrienne Waks, Eric Winer (2019)
          Breast cancer will be diagnosed in 12% of women in the United States over the course of their lifetimes and more than 250 000 new cases of breast cancer were diagnosed in the United States in 2017. This review focuses on current approaches and evolving strategies for local and systemic therapy of breast cancer.
          Article 0 comments Cited 1285 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA†

            I E Krop, N Lin, K Blackwell … (2014)
            In a retrospective analysis of the EMILIA study, the rate of central nervous system (CNS) progression in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer was similar for trastuzumab emtansine (T-DM1) and for capecitabine–lapatinib. In patients with treated, asymptomatic CNS metastases at baseline, T-DM1 was associated with significantly improved overall survival versus capecitabine–lapatinib.
            Article 0 comments Cited 129 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Pyrotinib or Lapatinib Combined With Capecitabine in HER2–Positive Metastatic Breast Cancer With Prior Taxanes, Anthracyclines, and/or Trastuzumab: A Randomized, Phase II Study

              Fei Ma, Quchang Ouyang, Wei Li … (2019)
              Pyrotinib, an irreversible pan-ErbB inhibitor, showed promising antitumor activity and acceptable tolerability in a phase I trial. We assessed the efficacy and tolerability of pyrotinib versus lapatinib, both in combination with capecitabine, in women with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer in an open-label, multicenter, randomized phase II study.
              Article 0 comments Cited 128 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): Cancer Res Treat
                Title: Cancer research and treatment : official journal of Korean Cancer Association
                Publisher: Korean Cancer Association
                ISSN (Electronic): 2005-9256
                ISSN (Print): 1598-2998
                Publication date (Electronic): Apr 24 2020
                Affiliations
                [1 ] Department of Medical Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.
                [2 ] Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
                Article
                Publisher Item ID: crt.2019.633
                DOI: 10.4143/crt.2019.633
                PubMed ID: 32340083
                SO-VID: 6848c56c-c5fb-43f4-b968-e53538595f52
                History

                Keywords: HER2-positive breast cancer,Brain metastasis,Pyrotinib,Tyrosine kinase inhibitor,Lapatinib-treated
                Data availability:
                Keywords: HER2-positive breast cancer, Brain metastasis, Pyrotinib, Tyrosine kinase inhibitor, Lapatinib-treated

                Comments

                Comment on this article

                scite_

                Similar content588

                See all similar

                Cited by22

                See all cited by

                Most referenced authors387

                See all reference authors